Get Premium to unlock powerful stock data
Guardant Health Inc logo

Guardant Health Inc $ 70.72 -2.0299 (-2.79%)

Volume:
1,592,650
Avg Vol (1m):
1,199,228
Market Cap $:
7.19 Bil
Enterprise Value $:
7.27 Bil
PE Ratio:
At Loss
PB Ratio:
10.42
Warning! GuruFocus has detected 2 Severe warning signs with GH. Click here to check it out.
Also Trade In: Germany Mexico
EMBED
10Y: -% Above Low: +NaN% Below High: NaN%
Peers
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for Guardant Health Inc () from 2018 to Jan 21 2022. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Guardant Health stock (GH) PE ratio as of Jan 21 2022 is 0. More Details

Guardant Health PE Ratio (TTM) Chart

EMBED

Guardant Health PE Ratio (TTM) Historical Data

Total 839
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 10
Guardant Health PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2022-01-21At Loss 2021-11-19At Loss
2022-01-20At Loss 2021-11-18At Loss
2022-01-19At Loss 2021-11-17At Loss
2022-01-18At Loss 2021-11-16At Loss
2022-01-17At Loss 2021-11-15At Loss
2022-01-14At Loss 2021-11-12At Loss
2022-01-13At Loss 2021-11-11At Loss
2022-01-12At Loss 2021-11-10At Loss
2022-01-11At Loss 2021-11-09At Loss
2022-01-10At Loss 2021-11-08At Loss
2022-01-07At Loss 2021-11-05At Loss
2022-01-06At Loss 2021-11-04At Loss
2022-01-05At Loss 2021-11-03At Loss
2022-01-04At Loss 2021-11-02At Loss
2022-01-03At Loss 2021-11-01At Loss
2021-12-31At Loss 2021-10-29At Loss
2021-12-30At Loss 2021-10-28At Loss
2021-12-29At Loss 2021-10-27At Loss
2021-12-28At Loss 2021-10-26At Loss
2021-12-27At Loss 2021-10-25At Loss
2021-12-24At Loss 2021-10-22At Loss
2021-12-23At Loss 2021-10-21At Loss
2021-12-22At Loss 2021-10-20At Loss
2021-12-21At Loss 2021-10-19At Loss
2021-12-20At Loss 2021-10-18At Loss
2021-12-17At Loss 2021-10-15At Loss
2021-12-16At Loss 2021-10-14At Loss
2021-12-15At Loss 2021-10-13At Loss
2021-12-14At Loss 2021-10-12At Loss
2021-12-13At Loss 2021-10-11At Loss
2021-12-10At Loss 2021-10-08At Loss
2021-12-09At Loss 2021-10-07At Loss
2021-12-08At Loss 2021-10-06At Loss
2021-12-07At Loss 2021-10-05At Loss
2021-12-06At Loss 2021-10-04At Loss
2021-12-03At Loss 2021-10-01At Loss
2021-12-02At Loss 2021-09-30At Loss
2021-12-01At Loss 2021-09-29At Loss
2021-11-30At Loss 2021-09-28At Loss
2021-11-29At Loss 2021-09-27At Loss
2021-11-26At Loss 2021-09-24At Loss
2021-11-25At Loss 2021-09-23At Loss
2021-11-24At Loss 2021-09-22At Loss
2021-11-23At Loss 2021-09-21At Loss
2021-11-22At Loss 2021-09-20At Loss

Guardant Health PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Guardant Health Inc logo

Business Description

Industry
Healthcare » Medical Diagnostics & Research » NAICS : 621511 SIC : 8071
Traded in other countries / regions
Address
505 Penobscot Drive, Redwood City, CA, USA, 94063
Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company's pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.